Wells Fargo’s Decibel Therapeutics, Inc. Common Stock DBTX Stock Holding History

Wells Fargo’s Portfolio DBTX Stock Details DBTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-94	Closed	-$362	–	7729
2023 Q2	$362	Buy	94 +4	+4%	+$15	﹤0.01%	6551
2023 Q1	$272	Buy	90 +2	+2%	+$7	﹤0.01%	6695
2022 Q4	$180	Buy	88 +2	+2%	+$6	﹤0.01%	6644
2022 Q3	$0	Buy	86 +38	+79%	+$173	﹤0.01%	7697
2022 Q2	$0	Buy	+48	New	+$113	﹤0.01%	7803
2021 Q4	–	Sell	-44	Closed	–	–	8068
2021 Q3	$0	Sell	44 -2	-4%	-$15	﹤0.01%	7743
2021 Q2	$0	Sell	46 -2,183	-98%	-$19.3K	﹤0.01%	7675
2021 Q1	$25K	Buy	+2,229	New	+$35K	﹤0.01%	6091

Other funds holding DBTX

ACA

Atlas Capital Advisors Jackson, Wyoming $875M AUM

Wells Fargo's DBTX Position: Q3 2023 in Review

Wells Fargo sold out of Decibel Therapeutics, Inc. Common Stock (DBTX) in Q3 2023, closing a stake of 94 shares — an estimated $362 sold.

Wells Fargo first reported a position in DBTX in Q1 2021 and held it in 8 quarters. The position peaked at $25K in Q1 2021. 1 fund tracked by Wall St. Rank holds DBTX as of Q3 2023.

Wells Fargo reported no remaining Decibel Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Wells Fargo sold 94 Decibel Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $362.
Wells Fargo first reported a position in Decibel Therapeutics, Inc. Common Stock in Q1 2021 and held it in 8 quarters.
Wells Fargo's Decibel Therapeutics, Inc. Common Stock position peaked at $25K in Q1 2021.
1 fund tracked by Wall St. Rank held Decibel Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Wells Fargo's 13F filing for Q3 2023, filed 13 Nov 2023.